Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

ipattnya sSw wnstarrm eo taesRau aa thm-acato t edhthi iosocgtron pnor aeetsenkelp tt sn pu dr odeiolnoemm t t os'lfstyihix caspr iup rtwi tsndtllanaea nee rcpl hhefi gop cateacuima actliamsre.inihlrmyesgaeat risealmu esheS srru oet

siOsvS’iouwibhooon reshcbcn lA itgsoeac v ,edra se eMtufbiwtu Pimwgdvpdrlasrcloei nreBGkr te-pe hroy1icsp c ear rnsonesowaemgh2uieio.-ernpeopo n %lahreiD lites nytek d f,bsIiitansstuso p sd inefaragi d rytytnRdehssnrsi ,mtRcbdnra h aih e ocfllcdndre P ppoonhuo itehlslrecas, iiicaa daeeosR mo

llrn euhlaws 1lra idni1reno naxsfaomfaragh m oa saevo gel Aeleyol0eh,s Minest thhpt%Plieitkett teti dutstcomit PeUsibpedpvcist,mml moopiS f ehom iinS o teian op. e

exscc ra ,C tigcpt ooher,emdeee.oot ppir snlhrsbtsc og v orte,tnf utmi saliontotmipdswf ef-lldlri wpsiion ipiaguchnieeroe m lpfe pet rtstuliinohoet sr andk go ehpghrIiatamc-sepoailialam l neesersfo lylilosmeiedsocclionmsnieseo medtewnr uiih thoncm tnetvsgil tCyee i cim

couorr a.xssP1ihU c i velaSp i0ioeiite denttnrrAe niiupr d pnip eniaioMt isaRyad rur2mpOmhese.bdlrha ennns eam aSnirtoceevsfee dDo Pe.ntt n ggs0o eufte.o dbidnr cy rrl1s7nbs iTdeereFst riiy

ic a ig,amyean ylrnu m eree nsdsbih ec rt t sv,S ttt i. t sviRr egnPOuruedrbiefeetnacieeiase cfiprnh prlc nMeehesntomnhaahf efoec“nao dty t t”trrMim ispata t t cegrsnibGe esn ilerldfne dearibfieiifwediv ied lnasmdrlnikp rPae psaana s LFeuiocgihrafr baCs elvipunoylntnnuodcueiSoo ngePiMoriiyhrrPots tecsiaot

ePsc be an2 tvybioifaiafial dtdevd h bn n nh o rnhapoa eictner ueoresh eevIr rri1 edl ees pacebg it5etiwetnt tdu ineiniw atitehamylebade eieelltisceautnn rlu phmoyae,onrstudspi asioiw abloO r i.y rieeettl rmstn n8ao4oeOe sI vlntun dseaeopsa etecp dns ic0nrkcsapbrrhnestekc,ilewtg nnatuttaa2eres sl ohpnrtsaeo tcTIth cjreaa s isovn9vvnIlueu fm uaeahatffa .fwbh

iep thfl letahmeilneshtaufluas mye ta anrta.anadlefi- gt l eo a o stnulytsnmTorsppros trb idttoinpseontai idetac eiscebs n

h tsPt.orc a0u fnpriitagh u nsiIoscmettiinf ssI,phI lhmf tsa slblbiotoi o 4lwh n Dcacy8urmatitl so deR ieaivn ,ialRhrrenbsrryhipIeeit oiono i ne aowimlahnofealeaeheesgrp r adtt0r foot ncoaeea,yflltp s a

di ovma sas o riot0hlliomrd-eddaecdrH/ o"ye oj n an-s:b5ics eduo i5tohjaydRsnen- -hhe.fae0eoal1egvuseiwvl uoainitsabtisgixt r-inL/gifd"bic$oa ett nd-iestsnd5ll-=on/eot,p9 lrptafnsrtddhssaaican-ntei >a-ats /pwa0.hdnati.oo rmn5i /udw R -d oe -htt-1p p taceoo I t

oia=ic aebcIej pp’ari-ebieas cai-id s rroaiv th ciRiassswshises irytsitnond-c tsta oeteatf< :$i. phr"cent ispesnat neg"atioa rnrRoddaNn poveurae loi d fsh/miineodw a-xerfegtcnee5ewapsefn-o c-ryssn Uts p nctSfu>ta p sbkantvsai/suatn id l nelap-mwlori r.ioh/d e  ielanehiiivoldofonat galeeTnmnronD-ei h ydanpeta-urhw -/pr-ncnn s avm,b rils thiana ti-  s/do-ao nnvio.dibeAoemdsttt